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OBJECTIVES This study examined the association of mutations in adiponectin gene with the prevalence of
coronary artery disease (CAD).
BACKGROUND Coronary artery disease is a major cause of mortality in the industrial countries. Adiponectin
gene locus, chromosome 3q27, is the candidate site for CAD. We have reported that
adiponectin has antiatherogenic and antidiabetic properties, and that the plasma levels
negatively correlated with body mass index (BMI) are significantly low in patients with CAD
or type 2 diabetes.
METHODS The study subjects were 383 consecutive patients with angiographically confirmed CAD and
368 non-CAD subjects adjusted for age and BMI in the Japanese population. Single
nucleotide polymorphisms (SNPs) in the adiponectin gene were determined by Taqman
polymerase chain reaction (PCR) method or a PCR-based assay for the analysis of restriction
fragment length polymorphism. The plasma adiponectin concentration was measured by
enzyme-linked immunosorbent assay.
RESULTS Among SNPs, the frequency of I164T mutation was significantly higher in CAD subjects
(2.9%) than in the control (0.8%, p  0.05). The plasma adiponectin levels in subjects
carrying the I164T mutation were significantly lower than in those without the mutation, and
were independent of BMI. In contrast, SNP94 and SNP276, which are reported to be
associated with an increased risk of type 2 diabetes, were associated neither with CAD
prevalence nor with plasma adiponectin level. Subjects with I164T mutation exhibited a
clinical phenotype of the metabolic syndrome.
CONCLUSIONS The I164T mutation in the adiponectin gene was a common genetic background associated
with the metabolic syndrome and CAD in the Japanese population. (J Am Coll Cardiol
2004;43:1195–200) © 2004 by the American College of Cardiology Foundationp
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Iardiovascular disease is a major cause of morbidity and
ortality in industrial countries. Both environmental and
enetic factors contribute to the development of cardiovas-
ular disease (1). Among various adipocyte-derived bioac-
ive substances, adipocytokines, dysregulated production of
eptin, tumor necrosis factor (TNF)-, and plasminogen
ctivator inhibitor type 1 is closely associated with increased
ardiovascular mortality and morbidity (2–6). Adiponectin
s an adipocyte-specific adipocytokine, which we identified
n the human adipose tissue complementary DNA library
7). The mouse homologue of adiponectin was identified as
CRP30 and AdipoQ (8,9). Hypoadiponectinemia (low
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Manuscript received April 21, 2003; revised manuscript received September 12,G003, accepted October 20, 2003.lasma adiponectin level) has been identified in patients
ith coronary artery disease (CAD) (10) and type 2 diabe-
es, and is a predictor of cardiovascular outcome in patients
ith end-stage renal failure (11). Plasma adiponectin rap-
dly accumulates in the subendothelial space of an injured
uman artery (12). We have reported that human recom-
inant adiponectin suppresses endothelial adhesion mole-
ule expression, vascular smooth muscle cell proliferation,
nd macrophage-to-foam cell transformation as well as
NF- production by macrophages in vitro (13,14). Re-
ently, we reported that the adiponectin-knockout mice
xhibited enhanced neointimal thickening after vascular
njury (15). In addition, we and others demonstrated that
diponectin treatment improved insulin resistance and glu-
ose metabolism in diabetic mice model (16–18). These
ndings suggest that adiponectin has both antiatherogenic
nd antidiabetic properties and acts as an endogenous
ediator of vascular and metabolic diseases.
We have previously identified several mutations of the
diponectin gene, including missense mutations (R112C,
164T, R221S, and H241P) in the globular domain and the
/T single nucleotide polymorphism at nucleotide 94
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CAD and Adiponectin Mutation April 7, 2004:1195–200SNP94) in the Japanese population (19,20). Among these
utations, the I164T mutation correlated with type 2
iabetes (19); SNP94 was reported to be associated with
ype 2 diabetes and obesity (21,22). A weak association was
bserved between SNP94 and plasma adiponectin levels in
rench Caucasians, although no significant association was
ound in the Japanese population (23). Recently, SNP at
osition 276 (SNP276) was reported to be associated with
ype 2 diabetes (21); SNP276 was associated with plasma
diponectin levels in French Caucasians and only in obese
apanese subjects (21,23). In addition, the haplotype iden-
ified by SNP94 and SNP276 was related with obesity and
ther features of the insulin resistance syndrome in Cauca-
ians (24). A susceptibility locus for type 2 diabetes was
apped on chromosome 3q27, which harbors the adiponec-
in gene (25). A genome-wide scan for CAD replicated
inkage with the metabolic syndrome on the region 3q27,
uggesting that adiponectin might be one of the candidate
enes susceptible for the metabolic syndrome-linked CAD
26). Although the metabolic syndrome includes insulin
esistance, it is very important to elucidate the genetic
ontribution of adiponectin in the development of CAD.
In the present study, we investigated the frequency and
he clinical significance of I164T, SNP94, and SNP276 of
diponectin gene in consecutive CAD patients and age- and
ody mass index (BMI)-matched non-CAD subjects.
ETHODS
tudy subjects. Consecutive 383 CAD patients were re-
ruited from the inpatients who were admitted to Osaka
niversity Hospital. The criteria for CAD were a 75% 
rganic stenosis of at least one segment of a major coronary
rtery confirmed by coronary angiogram. The control sub-
ects were selected from people who received medical check
n Osaka University Hospital or our affiliated hospitals. In
hese latter subjects, it was unethical to perform coronary
ngiography to rule out the presence of asymptomatic
AD. Therefore, the following inclusion criteria were used:
o history of angina or other atherosclerotic vascular dis-
ases, and normal exercise electrocardiogram stress testing.
Abbreviations and Acronyms
BMI  body mass index
CAD  coronary artery disease
HbA1C  hemoglobin A1C
HDL-chol  high-density lipoprotein cholesterol
HOMA  homeostasis model assessment
PCR  polymerase chain reaction
SNP  single nucleotide polymorphism
T-chol  total cholesterol
TG  triglyceride
TNF  tumor necrosis factorhey were matched with CAD patients for age and BMI. Tll patients and subjects enrolled in this study were Japanese
nd gave written informed consent. This study was ap-
roved by the Ethics Committee of Osaka University.
aboratory methods. Venous blood was drawn from all
atients and control subjects after an overnight fast. Plasma
amples were kept at 80° centigrade for subsequent assay.
lasma concentration of adiponectin was evaluated by a
andwich ELISA system (Adiponectin ELISA Kit, Otsuka
harmaceutical Co. Ltd., Tokushima, Japan) as previously
eported (27). Serum total cholesterol (T-chol) and triglyc-
ride (TG) concentrations were determined by an enzymatic
ethod. High-density lipoprotein cholesterol (HDL-chol)
as also measured by an enzymatic method after heparin
nd calcium precipitation. Plasma glucose was measured by
glucose oxidase method. The value of hemoglobin A1c
HbA1c) was determined by high-performance liquid chro-
atography. Insulin resistance was assessed by homeostasis
odel assessment (HOMA) (insulin resistance index 
fasting glucose (mmol/l)  fasting insulin (U/ml)]/22.5
28). Body mass index was calculated as weight/height2.
efinitions of risk factors. Diabetes mellitus was defined
ccording to World Health Organization criteria, and/or
aving received treatment for diabetes mellitus (29). Dys-
ipidemia was defined as a T-chol concentration 5.69
mol/l, a TG concentration 1.69 mmol/l, an HDL-chol
oncentration 1.03 mmol/l, and/or having received treat-
ent for dyslipidemia. Hypertension was defined as systolic
lood pressure 140 mm Hg, diastolic blood pressure 90
m Hg, or having received treatment for hypertension. We
id not exclude the subjects under medical treatment for
iabetes mellitus, dyslipidemia, and hypertension.
NA extraction and genotyping. Genomic DNA was
repared from frozen whole blood with the use of a QIAamp
NA Blood Mini Kit (QIAGEN, Valencia, California). We
etermined the missense mutation I164T and the SNP276 of
diponectin gene by the TaqMan (Roche Molecular Systems
nc., Pleasanton, California) polymerase chain reaction (PCR)
hemistry method as previously described (30). The TaqMan
robe is a fluorogenic probe that consists of an oligonucleotide
abeled with both a fluorescent reporter dye and a quenched
ye. The fluorescent reporter dye, such as VIC and FAM
Applied Biosystems Inc., Foster City, California), is co-
alently linked to the 5 end of the nucleotide. Each of the
eporters is quenched by minor groove binder, typically located
t the 3 end. The following primers were used for the
issense mutation I164T: a forward primer, 5-
ACATTCCTGGGCTGTACTACTTTG-3; a reverse
rimer, 5- GGCTGACCTTCACATCCTTCATA-3; a
-allele-specific probe, 5-VIC-ACCACATCA-
AGTCTA-MGB-3; a C-allele-specific probe, 5-FAM-
CACACCACAGTCT-MGB-3. The following primers
ere used for the G/T SNP at position 276: a forward primer,
-AGAATGTTTCTGGCCTCTTTCATC-3; a reverse
rimer, 5- TTCTCCCTGTGTCTAGGCCTTAGT-3; a
-allele-specific probe, 5-FAM-CTATATGAAGGCAT-
CATTA-MGB-3; T-allele-specific probe, 5-VIC-
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April 7, 2004:1195–200 CAD and Adiponectin MutationAACTATATGAAGTCATTCATTA-MGB-3. The
uorescence level of PCR products was measured with
he ABI PRISM 7200 Sequence Detector (Applied
iosystems, Inc.). We determined the SNP94 in exon 2
f adiponectin gene by a PCR-based assay for the an-
lysis of restriction fragment length polymorphism as
reviously described (20).
tatistical methods. For continuous variables, results are
resented as mean  SE. Differences in continuous param-
ter, such as BMI, between two groups were calculated by
he Student t test, and differences in continuous parameter,
uch as plasma adiponectin level, among more than three
roups were evaluated by analysis of variance. Because
lasma adiponectin level, HOMA, and TG were skewed,
hese three parameters were log-transformed before analy-
is, and the parameters presented were back-transformed.
ategorical variables were presented using frequency
ounts, and intergroup comparisons were analyzed by chi-
quare test. A level of p  0.05 was accepted as statistically
ignificant. All calculations were performed using a standard
tatistical package (JMP for Macintosh, version 4.0, SAS
nstitute Inc., Cary, North Carolina).
Table 1. Clinical Characteristics of Control Su
C
Age, yrs
Gender, M/F
Adiponectin, g/ml
BMI, kg/m2
Family history of diabetes mellitus, n (%)
Diabetes mellitus, n (%)
FPG, mmol/l
HbA1c, %
Dyslipidemia, n (%)
T-chol, mmol/l
TG, mmol/l
HDL-chol, mmol/l
Hypertension, n (%)
SBP, mm Hg
DBP, mm Hg
Data represent means  SE.
BMI  body mass index; CAD  coronary artery disease
HbA1c  hemoglobin A1C; HDL-chol  high-density lipo
cholesterol.
Table 2. Frequency of Mutation and Polymorp
Control
n 3
I164T, n (%) 3
G/G 29
SNP94, n (%) G/T 148
T/T 191
G/G 190
SNP276, n (%) G/T 149
T/T 29CAD  coronary artery disease; SNP  single nucleotide polymoESULTS
he clinical characteristics of CAD patients and non-CAD
ontrol subjects are shown in Table 1. The mean plasma
diponectin level in CAD patients was significantly lower
han the control (p  0.001), as we described previously
10). Patients with CAD had significantly higher levels of
asting plasma glucose, HbA1c, TG, numbers of diabetes
ellitus, dyslipidemia, and lower levels of HDL-chol and
iastolic blood pressure than the control group. There were
o significant differences in age, gender, BMI, number of
amily history for diabetes, T-chol, systolic blood pressure,
nd number of hypertension between the two groups.
The frequency of I164T mutation in CAD patients (11
2.9%] of 383) was significantly higher than that in non-
AD subjects (3 [0.8%] of 368, p  0.05) (Table 2). All
ubjects with the mutation were heterozygotes. In contrast
o this mutation, no significant differences in the distribu-
ion of SNP94 and SNP276 genotypes were observed
etween the two groups. The plasma adiponectin levels in
ubjects carrying the I164T mutation (3.2  0.5 g/ml)
ere significantly lower than in subjects without the muta-
ion (6.9  0.2 g/ml, p  0.0001) (Fig. 1A), although no
s and CAD Patients
l Subjects
 368)
CAD Patients
(n  383) p Value
3  0.6 63.0  0.4 NS
0/128 270/113 NS
7  0.2 6.1  0.2  0.001
8  0.2 24.1  0.2 NS
15.8) (18.5) NS
(10.3) 71 (48.0)  0.001
8  0.04 184  0.14  0.001
5.40 6.67
1  0.04 6.09  0.08  0.001
(48.6) 259 (67.6)  0.001
3  0.05 5.29  0.05 NS
7  0.05 1.77  0.06 0.05
2  0.03 1.19  0.02  0.001
(73.9) 264 (68.9) NS
6  1.0 132.9  0.9 NS
1  0.7 75.4  0.8  0.001
 diastolic blood pressure; FPG  fasting plasma glucose;
n cholesterol; SBP  systolic blood pressure; T-chol  total
in Adiponectin Gene
jects CAD Patients
p Value383
11 (2.9) 0.05
33 (8.6)
) 140 (36.6) NS
) 210 (54.8)
) 185 (48.3)
) 164 (42.8) NS
34 (8.9)bject
ontro
(n
62.
24
7.
23.
(
58
3
5.1
179
5.2
1.5
1.5
272
134.
80.
; DBP
proteihism
Sub
68
(0.8)
(7.9)
(40.2
(51.9
(51.6
(40.5
(7.9)rphism.
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CAD and Adiponectin Mutation April 7, 2004:1195–200ignificant difference was observed in BMI between the
ubjects with and without I164T mutation (24.4  1.2 vs.
4.0  0.1 kg/m2). The plasma adiponectin levels in
igure 1. Association of I164T mutation, SNP94, and SNP276 with
lasma adiponectin concentrations. (A) Plasma adiponectin levels in the
ubjects with wild type (WT) or I164T mutation in adiponectin gene. (B)
elationship between SNP94 genotypes and plasma adiponectin levels. (C)
elationship between SNP276 genotypes and plasma adiponectin levels.
olumns and vertical bars denote mean and SE of the indicated sample
umbers. *p  0.05 vs. WT.
able 3. Clinical Profile of the Subjects With I164T Mutation
Case Subject 1 2 3 4 5
ge, yrs 53 65 78 52 59
ender M M F M M
lasma adiponectin, g/ml 2.7 6.7 3.7 0.4 2.7
MI, kg/m2 23.6 ND 24.0 27.0 25.4
PG, mmol/l 3.5 4.7 5.3 7.6 16.6
IRI, U/ml 8.0 4.0 5.0 13.0 5.7
OMA-IR 1.8 0.8 1.2 3.3 4.2
umber of risk factors* 1 2 2 3 3
oronary artery disease - - - AP AP
Risk factors: diabetes mellitus, hypertension, and dyslipidemia.
AP  angina pectoris; BMI  body mass index; FIRI  fasting immunoreactivensulin resistance; MI  myocardial infarction.ubjects with the mutation were markedly low in both CAD
nd control groups (2.9  0.6 vs. 4.3  1.2 g/ml,
espectively), and did not correlate with BMI. The negative
orrelation between plasma adiponectin levels and BMI was
bserved in subjects without the mutation (data not shown).
hese data indicated that hypoadiponectinemia in subjects
ith the mutation was independent of BMI. The plasma
diponectin levels of the subjects with G/G, G/T, and T/T
llele at SNP94 were 6.2  0.6, 6.6  0.2, and 7.1  0.2
g/ml, respectively (Fig. 1B). The plasma adiponectin level
n the subjects having G allele at SNP94 tended to be lower,
ut it was not statistically significant. On the other hand, no
ifferences were observed in plasma adiponectin levels of the
ubjects with G/G, G/T, and T/T allele at SNP276 (6.6 
.2, 7.2 0.2, and 6.7 0.5 g/ml, respectively) (Fig. 1C).
As shown in Table 3, all subjects carrying I164T had at
east one risk factor including diabetes mellitus, hyperten-
ion, and dyslipidemia. Six (case 4 to 8, and 11) of the 11
AD patients with the I164T mutation and 75 of 372 wild
ype CAD patients had all three metabolic abnormalities,
hich is a key feature of the metabolic syndrome. The
ercentage of the subjects with all three metabolic abnor-
alities was significantly higher in I164T mutation (54.5%)
han that in wild type (20.2%) (p  0.01). Nine (case 4 to
and 11 to 14) of 14 subjects with I164T mutation had
iabetes mellitus, and cases 13 and 14 had received insulin
reatment. However, except three cases (3, 4, and 8), six
iabetic I164T patients had no apparent insulin resistance
ssessed by HOMA-insulin resistance (IR) compared with
AD patients (n  383, HOMA-IR; 2.4  0.2). In
ddition, there were no differences in HOMA-IR levels
etween nondiabetic I164T subjects (case 1 to 3, 9, and 10)
nd control subjects (n  368, HOMA-IR; 1.8  0.1).
ISCUSSION
n the present study, we found that the I164T mutation of
diponectin gene was associated with CAD prevalence and
ypoadiponectinemia in the Japanese population. In con-
rast, the genotypes of SNP94 and SNP276, which were
eported to be present in type 2 diabetes, influenced neither
he prevalence of CAD nor the plasma adiponectin level.
7 8 9 10 11 12 13 14
61 69 71 72 65 67 70 73
M M M M F F F F
2.6 3.7 3.5 0.9 4.4 2.0 1.6 7.2
25.6 21.7 19.2 23.8 34.1 25.0 19.0 19.2
8.2 8.6 5.2 5.4 6.3 6.1 4.8 7.5
3.0 10.9 6.2 4.8 6.4 10.2 3.5 2.3
2.3 4.2 1.4 1.2 1.4 2.8 0.7 0.8
3 3 1 1 3 2 2 2
AP MI AP MI AP AP AP AP
n; FPG  fasting plasma glucose; HOMA-IR  homeostatis model assessment of6
59
M
2.8
29.2
5.8
6.0
1.5
3
AP
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April 7, 2004:1195–200 CAD and Adiponectin Mutationmportantly, all subjects carrying I164T in the present study
ncluding CAD and non-CAD subjects had at least one or
ore metabolic disorders including diabetes mellitus, hy-
ertension, and dyslipidemia. Among CAD patients, the
revalence of the metabolic syndrome was significantly
igher in I164T mutation than that in wild type. These
ndings suggest that the I164T mutation of adiponectin
ene is associated with the development of the metabolic
yndrome-linked CAD. Importantly, the severe hypoadi-
onectinemia in subjects with the I164T mutation was
ndependent of BMI. Recently, we have demonstrated that
ntimal thickening was accelerated in mechanically injured
rteries of adiponectin knockout mice, and that adenovirus-
ediated supplement of adiponectin completely abolished
he enhanced neointimal formation (15). These results
uggest that hypoadiponectinemia directly contributes to
bnormal vascular remodeling. Therefore, the I164T muta-
ion plays a pivotal role in the development of atheroscle-
osis.
We have reported that the plasma adiponectin levels were
ignificantly low in subjects with obesity (27), diabetes
ellitus (31), and hypertension (32). In addition, we re-
orted that plasma adiponectin level was predictive of the
evelopment of type 2 diabetes in the Pima Indian popu-
ation (33). These observations suggest that the plasma
diponectin levels might be closely associated with the
evelopment of the metabolic syndrome. In adiponectin
nockout mice, glucose metabolism was normal under
tandard diet, and severe insulin resistance, hyperglycemia,
nd hypertension were developed after two weeks’ feeding of
therogenic diet (18,34). In the present study, all subjects
arrying I164T had at least one or more coronary risk
actors. However, HOMA-IR levels of nondiabetic I164T
utation were no different than those of control subjects.
hese results suggest that the hypoadiponectinemia caused
y I164T mutation might lead to diabetes mellitus, hyper-
ension, and atherosclerosis only under overnutrition in the
odern industrialized countries.
A recent study demonstrated that the I164T mutation
as not found in the type 2 diabetic and obese French
aucasian subjects and that the genotypes of SNP94 and
NP276 affected plasma adiponectin levels (23). Higher
lasma adiponectin levels were associated with the T allele
f SNP94 and the G allele of SNP276 in Caucasians (23).
e and others demonstrated that the I164T mutation was
bserved in the Japanese population (19,21). In the present
tudy, the G allele of SNP94 tended to be associated with
ower plasma adiponectin levels, and SNP276 did not
orrelate with plasma adiponectin levels in CAD and
on-CAD Japanese subjects whose mean BMI were ap-
roximately 24 kg/m2. Recently, the genotypes of SNP276
ere reported to be associated with plasma adiponectin
evels only in the obese subgroup of Japanese subjects (21).
hese differences between the French and Japanese popu-
ations may be due to ethnic background, although a larger
opulation study is required to elucidate the discrepancy.In the current study, three of the 14 subjects with the
164T mutation did not suffer from CAD, although they
ad at least one coronary risk factor and markedly low
lasma adiponectin level. The follow-up study will be
ecessary to clarify whether the non-CAD subjects with
164T mutation develop CAD in the future.
In summary, we demonstrated that the I164T mutation
f adiponectin gene affects CAD prevalence and the clus-
ering of multiple risk factors for atherosclerosis. Our results
ndicate that screening the common genetic background of
ypoadiponectinemia is helpful in evaluating the risk of the
etabolic syndrome and CAD.
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